Long-term systemic administration of the SIRT6 agonist MDL-800 preserved intervertebral disc structure, cell viability, and matrix quality in 24-month-old mice, with reduced senescence markers and increased autophagy. The treatment was systemically well tolerated, though investigators noted a modest reduction in vertebral structural parameters and mild hyperalgesia. Disc degeneration is a principal driver of chronic low back pain and mobility loss in later life, making pharmacological maintenance of spinal tissue a relevant target for healthspan.
Key Points
- SIRT6 agonist MDL-800 lowered disc degeneration scores in aged mice
- Senescence markers p21, IL-6, TGF-β, and CCL2 declined
- Autophagy increased; epigenetic marks including H3K9ac were reduced
Longevity Analysis
Spinal discs are among the least vascularized and slowest-regenerating tissues in the body, which makes them an early and unforgiving indicator of how well cellular repair and waste-clearance machinery is holding up with age. Targeting an NAD+-dependent enzyme that governs chromatin state, autophagy, and the inflammatory output of senescent cells addresses degeneration at its source rather than managing the pain it produces downstream. The reported trade-offs — slightly reduced vertebral structural parameters and mild hyperalgesia — are a reminder that interventions acting on systemic repair pathways require careful monitoring of the surrounding skeletal framework and pain signaling, not just the target tissue.
Original published by Wiley Aging Cell, by Pranay Ramteke, Bahiyah Watson, Sanjana Jagannath, Sarah E. Bell, Mallory Toci, Olivia Ottone, Qinglin Wu, Oliver Abinader, Ramkrishna Mitra, John A. Collins, Ruteja A. Barve, Makarand V. Risbud .